Novo Nordisk's trial with amycretin shows significant weight loss potential.

From GlobeNewswire: 2025-01-24 05:19:59

Novo Nordisk reported positive topline results from a phase 1b/2a clinical trial with amycretin, a GLP-1 and amylin receptor agonist for overweight or obese individuals. The trial showed a 9.7% to 22.0% body weight loss in those treated with amycretin, compared to a 1.9% to 2.3% weight gain in the placebo group. The safety profile of amycretin was consistent with other incretin-based therapies, with mostly mild to moderate gastrointestinal side effects. Novo Nordisk plans to continue clinical development of amycretin for adults with overweight or obesity, as well as for type 2 diabetes.



Read more at GlobeNewswire: Novo Nordisk successfully completes phase 1b/2a trial with